Nine patients in the avelumab monotherapy arm crossed over to the avelumab plus cetuximab group and the median PFS after crossover was 11.3 months (5.8-NR). The median overall survival (OS) of the ...

Avelumab + cetuximab significantly improved PFS versus avelumab (median, 11.1 [7.6-not reached (NR)] v 3.0 months [2.7-13.6] hazard ratio, 0.48 [95% CI, 0.23 to 0.97], P = .018). Avelumab patients who ...

Avelumab is an immune checkpoint inhibitor drug that targets a protein found on cancer cells called PD-L1. When PD-L1 binds to a receptor on T cells called PD-1, it acts like a brake, slowing down ...

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results Alliance A091802 is ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Meanwhile, in April, NICE backtracked on Merck KGaA/Pfizer’s Bavencio (avelumab), previously having said it was too expensive for routine NHS use as a first-line maintenance treatment for UC ...

The German group is also facing slowing sales growth for its cancer immunotherapy Bavencio (avelumab) and the looming patent expiry for MS drug Mavenclad (cladribine), which together accounted for ...

May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had ...